Marty Makary, nominated to lead the Food and Drug Administration, has articulated positions on drug approval that threaten to slow the pace of breakthrough treatments reaching patients who desperately need them.
The heart of the problem lies in Makary's apparent resistance to adaptive approval pathways and accelerated review processes that have become essential tools for bringing novel therapies to market faster. These mechanisms exist precisely because traditional approval timelines can delay access to transformative medicines.
The FDA faces a fundamental challenge: balancing safety oversight with the urgent reality that patients cannot wait years for drugs that might extend or save their lives. Accelerated pathways do not circumvent safety standards. Instead, they recognize that some conditions justify faster review without compromising the evidence required for approval.
Makary's stance suggests a skepticism toward innovation that could prove costly. Cancer patients, rare disease sufferers, and others facing life-threatening conditions depend on the agency's willingness to move quickly when the science supports it. Regulatory caution has its place, but excessive risk aversion becomes its own form of harm.
The FDA leadership position demands someone who grasps both the necessity of robust oversight and the moral imperative of access. A commissioner must understand that patients weigh risks and benefits differently than bureaucrats do, and that their voices matter in this equation.
The question now is whether Makary's views represent fixed principle or positions that can evolve once he understands the full weight of the job. The FDA cannot afford a leader who treats innovation as an inconvenient complication rather than a core mission.
Author James Rodriguez: "The FDA needs leaders willing to move at the speed of science, not the speed of caution."
Comments